Peptides · Men

Peptides for men over 40

The peptide market is unregulated. What the published evidence actually says about BPC-157, TB-500, sermorelin, ipamorelin, and the rest.

Peptide therapy is having a moment in the longevity space. Most of what you read about it online is marketing from compounding pharmacies. Some of the underlying science is genuinely interesting. Most of the human trial evidence is thin or non-existent.

The honest landscape

BPC-157. Synthetic gastric peptide. Strong rodent evidence for tendon and gut healing. Zero peer-reviewed human RCTs. Most clinical use is off-label / compounded. The biological plausibility is real; the human data is not yet.

TB-500 (thymosin beta-4 fragment). Similar story. Athletic recovery claims dominant. Sparse controlled human evidence.

Sermorelin / Ipamorelin / CJC-1295. Growth hormone secretagogues. Stimulate the pituitary to release GH in a more physiologic pulsatile pattern than exogenous rhGH. Some published evidence in clinical GH-deficiency populations; sparse evidence in healthy adults seeking longevity benefit.

Semaglutide / Tirzepatide. These are the GLP-1 / GIP agonists. Real, large, RCT-grade evidence for weight loss and glycemic improvement. These are FDA-approved medications, not grey-market peptides. Different category.

What to actually think about before injecting anything

The honest take

The published human evidence base for most peptides — outside of the GLP-1 class — does not support the confidence level of typical marketing. The biological plausibility is genuine for several compounds. The question is whether you want to be among the people who try things before the RCTs catch up.

If you do: work with a licensed clinician, use a 503B compounding pharmacy, document baselines, track outcomes, stop if anything goes sideways.

Take the Hormone Age Calculator →
Sources: Sikiric 2018 review of BPC-157 mechanisms; Sinha 2014 on thymosin beta-4; Walker 2006 growth hormone secretagogue review; Wilding 2021 STEP-1 (semaglutide); Jastreboff 2022 SURMOUNT-1 (tirzepatide).